Sodium-Glucose Cotransporter2 inhibitors and associated Liver-Related outcomes in diabetes patients

Sodium-glucose cotransporter-2 inhibitor (SGLT-2i) use is associated with a 52% lower risk of all-cause mortality in type 2 diabetes patients.

• SGLT-2i users showed a significantly lower risk of liver cirrhosis (adjusted hazard ratio [aHR] 0.78).
• The risk of decompensated cirrhosis was also lower in SGLT-2i users (aHR 0.79).
• SGLT-2i use was linked to a reduced risk of liver failure (aHR 0.78).
• Comparisons with other antidiabetic medications indicated that SGLT-2i was associated with lower risks of cirrhosis and liver failure.
• SGLT-2i users experienced lower liver-related mortality compared to those using dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists.

AI simplified